Interleukin-23 inhibition for psoriasis shows ‘wow’ factor Most patients with moderate to severe plaque psoriasis on either guselkumab or tildrakizumab have at least PASI 90 sustained response at 2… mdedge.com FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis Ilumya (tildrakizumab-asmn) is used to treat moderate-to-severe plaque psoriasis. drugs.com|By Drugs.com Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis mdedge.com